Which has higher valuation & earnings, GSK or ONC?

GSK has higher revenue and earnings than BeOne Medicines. GSK is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GSK $43.07B 2.42 $7.54B $3.20 16.12 BeOne Medicines $5.34B 6.63 $286.93M $4.47 72.26

Is GSK or ONC more profitable?

GSK has a net margin of 14.56% compared to BeOne Medicines' net margin of 8.94%. GSK's return on equity of 43.23% beat BeOne Medicines' return on equity. Company Net Margins Return on Equity Return on Assets GSK 14.56% 43.23% 11.60% BeOne Medicines 8.94% 12.06% 6.69%

Does the media favor GSK or ONC?

In the previous week, GSK had 3 more articles in the media than BeOne Medicines. MarketBeat recorded 13 mentions for GSK and 10 mentions for BeOne Medicines. BeOne Medicines' average media sentiment score of 0.77 beat GSK's score of 0.52 indicating that BeOne Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GSK 5 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive BeOne Medicines 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, ONC or SNY?

Sanofi has higher revenue and earnings than BeOne Medicines. Sanofi is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BeOne Medicines $5.34B 6.63 $286.93M $4.47 72.26 Sanofi $49.35B 2.10 $8.84B $1.91 22.35

Is ONC or SNY more profitable?

BeOne Medicines has a net margin of 8.94% compared to Sanofi's net margin of 8.66%. Sanofi's return on equity of 14.19% beat BeOne Medicines' return on equity. Company Net Margins Return on Equity Return on Assets BeOne Medicines 8.94% 12.06% 6.69% Sanofi 8.66% 14.19% 7.95%

Does the media prefer ONC or SNY?

In the previous week, Sanofi had 18 more articles in the media than BeOne Medicines. MarketBeat recorded 28 mentions for Sanofi and 10 mentions for BeOne Medicines. Sanofi's average media sentiment score of 1.09 beat BeOne Medicines' score of 0.77 indicating that Sanofi is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sanofi 17 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Do analysts prefer ONC or TAK?

BeOne Medicines presently has a consensus target price of $394.00, suggesting a potential upside of 21.98%. Given BeOne Medicines' stronger consensus rating and higher possible upside, research analysts clearly believe BeOne Medicines is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BeOne Medicines 1 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 2 Strong Buy rating(s) 2.88 Takeda Pharmaceutical 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media favor ONC or TAK?

In the previous week, Takeda Pharmaceutical had 2 more articles in the media than BeOne Medicines. MarketBeat recorded 12 mentions for Takeda Pharmaceutical and 10 mentions for BeOne Medicines. BeOne Medicines' average media sentiment score of 0.77 beat Takeda Pharmaceutical's score of 0.74 indicating that BeOne Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Takeda Pharmaceutical 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is ONC or ARGX more profitable?

argenex has a net margin of 32.19% compared to BeOne Medicines' net margin of 8.94%. argenex's return on equity of 43.59% beat BeOne Medicines' return on equity. Company Net Margins Return on Equity Return on Assets BeOne Medicines 8.94% 12.06% 6.69% argenex 32.19% 43.59% 36.66%

Does the media favor ONC or ARGX?

In the previous week, argenex had 7 more articles in the media than BeOne Medicines. MarketBeat recorded 17 mentions for argenex and 10 mentions for BeOne Medicines. argenex's average media sentiment score of 0.91 beat BeOne Medicines' score of 0.77 indicating that argenex is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive argenex 9 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

BeOne Medicines (ONC) Competitors

$323.01 +9.24 (+2.94%)

Closing price 04:00 PM Eastern

Extended Trading

$323.10 +0.10 (+0.03%)

As of 04:15 PM Eastern

Compare

ONC vs. GSK, SNY, TAK, ARGX, and TEVA

Should you buy BeOne Medicines stock or one of its competitors? MarketBeat compares BeOne Medicines with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BeOne Medicines include GSK (GSK), Sanofi (SNY), Takeda Pharmaceutical (TAK), argenex (ARGX), and Teva Pharmaceutical Industries (TEVA).

How does BeOne Medicines compare to GSK?

GSK (NYSE:GSK) and BeOne Medicines (NASDAQ:ONC) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, earnings, institutional ownership, dividends, valuation and risk.

GSK has a beta of 0.36, suggesting that its share price is 64% less volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market.

GSK presently has a consensus target price of $53.00, indicating a potential upside of 2.77%. BeOne Medicines has a consensus target price of $394.00, indicating a potential upside of 21.98%. Given BeOne Medicines' stronger consensus rating and higher probable upside, analysts plainly believe BeOne Medicines is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	2 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.10
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.88

GSK has a net margin of 14.56% compared to BeOne Medicines' net margin of 8.94%. GSK's return on equity of 43.23% beat BeOne Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	14.56%	43.23%	11.60%
BeOne Medicines	8.94%	12.06%	6.69%

In the previous week, GSK had 3 more articles in the media than BeOne Medicines. MarketBeat recorded 13 mentions for GSK and 10 mentions for BeOne Medicines. BeOne Medicines' average media sentiment score of 0.77 beat GSK's score of 0.52 indicating that BeOne Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	5 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
BeOne Medicines	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

15.7% of GSK shares are owned by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are owned by institutional investors. 10.0% of GSK shares are owned by company insiders. Comparatively, 6.2% of BeOne Medicines shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

GSK has higher revenue and earnings than BeOne Medicines. GSK is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$43.07B	2.42	$7.54B	$3.20	16.12
BeOne Medicines	$5.34B	6.63	$286.93M	$4.47	72.26

Summary

BeOne Medicines beats GSK on 10 of the 17 factors compared between the two stocks.

How does BeOne Medicines compare to Sanofi?

BeOne Medicines (NASDAQ:ONC) and Sanofi (NASDAQ:SNY) are both large-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.

In the previous week, Sanofi had 18 more articles in the media than BeOne Medicines. MarketBeat recorded 28 mentions for Sanofi and 10 mentions for BeOne Medicines. Sanofi's average media sentiment score of 1.09 beat BeOne Medicines' score of 0.77 indicating that Sanofi is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sanofi	17 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

48.6% of BeOne Medicines shares are owned by institutional investors. Comparatively, 14.0% of Sanofi shares are owned by institutional investors. 6.2% of BeOne Medicines shares are owned by company insiders. Comparatively, 1.0% of Sanofi shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

BeOne Medicines has a net margin of 8.94% compared to Sanofi's net margin of 8.66%. Sanofi's return on equity of 14.19% beat BeOne Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	8.94%	12.06%	6.69%
Sanofi	8.66%	14.19%	7.95%

BeOne Medicines currently has a consensus target price of $394.00, indicating a potential upside of 21.98%. Sanofi has a consensus target price of $49.50, indicating a potential upside of 15.98%. Given BeOne Medicines' stronger consensus rating and higher possible upside, equities analysts plainly believe BeOne Medicines is more favorable than Sanofi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.88
Sanofi	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.47

BeOne Medicines has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market. Comparatively, Sanofi has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market.

Sanofi has higher revenue and earnings than BeOne Medicines. Sanofi is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	6.63	$286.93M	$4.47	72.26
Sanofi	$49.35B	2.10	$8.84B	$1.91	22.35

Summary

BeOne Medicines beats Sanofi on 10 of the 16 factors compared between the two stocks.

How does BeOne Medicines compare to Takeda Pharmaceutical?

BeOne Medicines (NASDAQ:ONC) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, media sentiment, valuation and risk.

BeOne Medicines has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.08, suggesting that its share price is 108% less volatile than the broader market.

In the previous week, Takeda Pharmaceutical had 2 more articles in the media than BeOne Medicines. MarketBeat recorded 12 mentions for Takeda Pharmaceutical and 10 mentions for BeOne Medicines. BeOne Medicines' average media sentiment score of 0.77 beat Takeda Pharmaceutical's score of 0.74 indicating that BeOne Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Takeda Pharmaceutical	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

BeOne Medicines has higher earnings, but lower revenue than Takeda Pharmaceutical. Takeda Pharmaceutical is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	6.63	$286.93M	$4.47	72.26
Takeda Pharmaceutical	$28.32B	1.88	-$1.01B	$0.34	48.75

BeOne Medicines has a net margin of 8.94% compared to Takeda Pharmaceutical's net margin of 3.80%. BeOne Medicines' return on equity of 12.06% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	8.94%	12.06%	6.69%
Takeda Pharmaceutical	3.80%	10.87%	5.32%

48.6% of BeOne Medicines shares are held by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are held by institutional investors. 6.2% of BeOne Medicines shares are held by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

BeOne Medicines presently has a consensus target price of $394.00, suggesting a potential upside of 21.98%. Given BeOne Medicines' stronger consensus rating and higher possible upside, research analysts clearly believe BeOne Medicines is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.88
Takeda Pharmaceutical	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

BeOne Medicines beats Takeda Pharmaceutical on 15 of the 17 factors compared between the two stocks.

How does BeOne Medicines compare to argenex?

BeOne Medicines (NASDAQ:ONC) and argenex (NASDAQ:ARGX) are both large-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.

argenex has a net margin of 32.19% compared to BeOne Medicines' net margin of 8.94%. argenex's return on equity of 43.59% beat BeOne Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	8.94%	12.06%	6.69%
argenex	32.19%	43.59%	36.66%

BeOne Medicines presently has a consensus target price of $394.00, indicating a potential upside of 21.98%. argenex has a consensus target price of $1,056.89, indicating a potential upside of 25.15%. Given argenex's stronger consensus rating and higher probable upside, analysts plainly believe argenex is more favorable than BeOne Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.88
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92

48.6% of BeOne Medicines shares are owned by institutional investors. Comparatively, 60.3% of argenex shares are owned by institutional investors. 6.2% of BeOne Medicines shares are owned by company insiders. Comparatively, 2.4% of argenex shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, argenex had 7 more articles in the media than BeOne Medicines. MarketBeat recorded 17 mentions for argenex and 10 mentions for BeOne Medicines. argenex's average media sentiment score of 0.91 beat BeOne Medicines' score of 0.77 indicating that argenex is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
argenex	9 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BeOne Medicines has a beta of 0.49, meaning that its share price is 51% less volatile than the broader market. Comparatively, argenex has a beta of 0.46, meaning that its share price is 54% less volatile than the broader market.

argenex has lower revenue, but higher earnings than BeOne Medicines. argenex is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	6.63	$286.93M	$4.47	72.26
argenex	$4.25B	12.44	$1.29B	$26.04	32.43

Summary

argenex beats BeOne Medicines on 12 of the 16 factors compared between the two stocks.

How does BeOne Medicines compare to Teva Pharmaceutical Industries?

BeOne Medicines (NASDAQ:ONC) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.

48.6% of BeOne Medicines shares are held by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. 6.2% of BeOne Medicines shares are held by insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

BeOne Medicines has a net margin of 8.94% compared to Teva Pharmaceutical Industries' net margin of 4.08%. Teva Pharmaceutical Industries' return on equity of 32.64% beat BeOne Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	8.94%	12.06%	6.69%
Teva Pharmaceutical Industries	4.08%	32.64%	6.34%

BeOne Medicines currently has a consensus price target of $394.00, indicating a potential upside of 21.98%. Teva Pharmaceutical Industries has a consensus price target of $42.00, indicating a potential upside of 22.02%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher probable upside, analysts plainly believe Teva Pharmaceutical Industries is more favorable than BeOne Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.88
Teva Pharmaceutical Industries	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90

Teva Pharmaceutical Industries has higher revenue and earnings than BeOne Medicines. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	6.63	$286.93M	$4.47	72.26
Teva Pharmaceutical Industries	$17.26B	2.29	$1.41B	$0.60	57.37

In the previous week, Teva Pharmaceutical Industries had 36 more articles in the media than BeOne Medicines. MarketBeat recorded 46 mentions for Teva Pharmaceutical Industries and 10 mentions for BeOne Medicines. Teva Pharmaceutical Industries' average media sentiment score of 0.83 beat BeOne Medicines' score of 0.77 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Teva Pharmaceutical Industries	27 Very Positive mention(s)	6 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive

BeOne Medicines has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market.

Summary

Teva Pharmaceutical Industries beats BeOne Medicines on 9 of the 17 factors compared between the two stocks.

Get BeOne Medicines News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ONC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ONC vs. The Competition

Export

Metric	BeOne Medicines	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$35.44B	$11.45B	$6.80B	$13.02B
Dividend Yield	N/A	2.74%	2.60%	10.03%
P/E Ratio	72.26	791.59	279.73	25.56
Price / Sales	6.63	948.13	649.61	116.36
Price / Cash	80.85	14.82	28.64	34.82
Price / Book	8.12	10.43	11.12	6.36
Net Income	$286.93M	$2.81B	$3.48B	$347.58M
7 Day Performance	-2.25%	1.93%	2.67%	3.24%
1 Month Performance	8.52%	-3.06%	-2.70%	-2.00%
1 Year Performance	6.15%	154.91%	64.43%	21.31%

BeOne Medicines Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ONC BeOne Medicines	4.5947 of 5 stars	$323.01 +2.9%	$394.00 +22.0%	+4.9%	$35.44B	$5.34B	72.26	12,000	Upcoming Earnings Insider Trade
GSK GSK	2.91 of 5 stars	$51.80 -0.5%	$53.00 +2.3%	+37.3%	$104.78B	$43.07B	16.20	66,841	Dividend Increase Analyst Downgrade
SNY Sanofi	3.6099 of 5 stars	$42.82 -0.2%	$49.50 +15.6%	-8.1%	$103.83B	$48.92B	11.96	74,846	News Coverage Analyst Upgrade Gap Up
TAK Takeda Pharmaceutical	1.9646 of 5 stars	$17.09 -1.0%	N/A	+18.9%	$54.74B	$4.62T	43.81	47,000	Gap Down
ARGX argenex	4.6169 of 5 stars	$857.16 -1.8%	$1,056.89 +23.3%	+23.3%	$53.62B	$4.25B	32.91	1,863	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ONC) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BeOne Medicines (ONC) Competitors

ONC vs. GSK, SNY, TAK, ARGX, and TEVA

How does BeOne Medicines compare to GSK?

Summary

How does BeOne Medicines compare to Sanofi?

Summary

How does BeOne Medicines compare to Takeda Pharmaceutical?

Summary

How does BeOne Medicines compare to argenex?

Summary

How does BeOne Medicines compare to Teva Pharmaceutical Industries?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONC vs. The Competition

BeOne Medicines Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BeOne Medicines (ONC) Competitors

ONC vs. GSK, SNY, TAK, ARGX, and TEVA

How does BeOne Medicines compare to GSK?

Which has more risk & volatility, GSK or ONC?

Do analysts recommend GSK or ONC?

Is GSK or ONC more profitable?

Does the media favor GSK or ONC?

Do insiders and institutionals have more ownership in GSK or ONC?

Which has higher valuation & earnings, GSK or ONC?

Summary

How does BeOne Medicines compare to Sanofi?

Does the media prefer ONC or SNY?

Do institutionals and insiders believe in ONC or SNY?

Is ONC or SNY more profitable?

Do analysts recommend ONC or SNY?

Which has more volatility and risk, ONC or SNY?

Which has stronger earnings & valuation, ONC or SNY?

Summary

How does BeOne Medicines compare to Takeda Pharmaceutical?

Which has more volatility & risk, ONC or TAK?

Does the media favor ONC or TAK?

Which has stronger earnings and valuation, ONC or TAK?

Is ONC or TAK more profitable?

Do insiders & institutionals hold more shares of ONC or TAK?

Do analysts prefer ONC or TAK?

Summary

How does BeOne Medicines compare to argenex?

Is ONC or ARGX more profitable?

Do analysts recommend ONC or ARGX?

Do institutionals & insiders believe in ONC or ARGX?

Does the media favor ONC or ARGX?

Which has more risk and volatility, ONC or ARGX?

Which has better earnings & valuation, ONC or ARGX?

Summary

How does BeOne Medicines compare to Teva Pharmaceutical Industries?

Do insiders & institutionals believe in ONC or TEVA?

Is ONC or TEVA more profitable?

Do analysts rate ONC or TEVA?

Which has stronger valuation & earnings, ONC or TEVA?

Does the media favor ONC or TEVA?

Which has more risk & volatility, ONC or TEVA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONC vs. The Competition

BeOne Medicines Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools